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Abstract
By virtue of its ability to regulate the composition of cerebrospinal fluid (CSF), the choroid plexus (CP) is ideally suited to
instigate a rapid response to traumatic brain injury (TBI) by producing growth regulatory proteins. For example, Esophageal
Cancer Related Gene-4 (Ecrg4) is a tumor suppressor gene that encodes a hormone-like peptide called augurin that is
present in large concentrations in CP epithelia (CPe). Because augurin is thought to regulate senescence, neuroprogenitor
cell growth and differentiation in the CNS, we evaluated the kinetics of Ecrg4 expression and augurin immunoreactivity in
CPe after CNS injury. Adult rats were injured with a penetrating cortical lesion and alterations in augurin immunoreactivity
were examined by immunohistochemistry. Ecrg4 gene expression was characterized by in situ hybridization. Cell surface
augurin was identified histologically by confocal microscopy and biochemically by sub-cellular fractionation. Both Ecrg4
gene expression and augurin protein levels were decreased 24–72 hrs post-injury but restored to uninjured levels by day 7
post-injury. Protein staining in the supraoptic nucleus of the hypothalamus, used as a control brain region, did not show a
decrease of auguin immunoreactivity. Ecrg4 gene expression localized to CPe cells, and augurin protein to the CPe
ventricular face. Extracellular cell surface tethering of 14 kDa augurin was confirmed by cell surface fractionation of primary
human CPe cells in vitro while a 6–8 kDa fragment of augurin was detected in conditioned media, indicating release from
the cell surface by proteolytic processing. In rat CSF however, 14 kDa augurin was detected. We hypothesize the initial
release and proteolytic processing of augurin participates in the activation phase of injury while sustained Ecrg4 down-
regulation is dysinhibitory during the proliferative phase. Accordingly, augurin would play a constitutive inhibitory function
in normal CNS while down regulation of Ecrg4 gene expression in injury, like in cancer, dysinhibits proliferation.
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Introduction
Traumaticbraininjury (TBI) is oftenassociated withpoor clinical
outcomes because an over exuberant inflammatory response can
cause unintended damage to both injured and non-injured central
nervous system (CNS) tissue [1]. In addition, there are biophysical
changes in the CNS that restrict functional recoveries. For example,
the formation of a glial scar after injury protects neurons from
excitotoxic factors [1,2] but blocks synaptic re-growth and
neuroprogenitor cell infiltration from the subventricular zone
(SVZ) [3]. Furthermore, edema may disrupt blood-brain (BBB)
and blood-cerebrospinal fluid (BCSFB) barriers, compress brain
parenchyma [4] and compromise endothelial, choroid plexus
epithelial (CPe), ventricular ependymal (Ve) and subarachnoid
(SA) cells that normally filter toxins from interstitial fluid, maintain
the ionic balance of CSF, and secrete hormones and growth factors
to maintain CNS homeostasis [5].
The CPe in particular suffers unique metabolic and structural
stresses during the acute stages of CNS injury, which restrict
functions that would otherwise restore homeostasis during repair.
For example, vasogenic edema after injury increases the volume of
the extracellular fluid compartment and causes ventriculomegaly.
The resulting mechanical stress [6] and neutrophil invasion [7]
increase leakiness of BCSFB tight junctions and sloughing of apical
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24609cilia from CPe and Ve cells. Furthermore, disrupted tight junctions
impair protein ultrafiltration and lead to increased bulk and
osmotic flow of water into CSF [8,9,10].
Among the peptides produced in, and regulated by, the CPe
[11,12], augurin is a newly described hormone-like protein that is
produced after proteolytic processing of the esophageal cancer related
gene-4 (Ecrg4) holoprotein [13] and is thought to play a role in
CNS homeostasis [14,15]. Previous reports [15] have shown that
Ecrg4 gene expression levels in the CNS are highest in CPe and
ependyma during both development (www.genepaint.org [16])
and in the adult CNS (www.brain-map.org [17]) and have
suggested a possible role for its product augurin in CNS
homeostasis. This hypothesis is supported by our observations
that knockdown of Ecrg4 gene expression during zebrafish
development induced cell over-proliferation in the developing
CNS and generated a ventriculomegaly phenotype. In contrast,
Ecrg4 overexpression in adult rat brain decreased cell proliferation
in the SVZ pool of adult neuroprogenitor cells following a cortical
stab model of CNS injury [14].
Here we show that there is a rapid loss of both augurin and
Ecrg4 gene expression in CPe after CNS injury. These data
support the hypothesis that augurin plays a constitutive inhibitory
function in the normal CNS and that its rapid release by and
subsequent disappearance from CPe after injury may help trigger
and sustain the CNS response to injury by enabling cell
proliferation.
Results
Augurin is a cell membrane protein
Immunohistochemical analyses of augurin in periventricular
regions of the brain (Figure 1A, red) showed that, in many
instances, the greatest intensity of augurin immunolabeling was
polarized (arrow) with significant staining localizing to the
ventricular side of CPe cells (red staining compared to DAPI
nuclear stain in blue). Furthermore, the pattern of immunoreac-
tivity in the cytoplasm of the CPe was granular, which may be
indicative of augurin’s presence in secretory vesicles (inset). In
contrast augurin immunoreactivity was not detected in CP
endothelium or at the abluminal face of CPe. This suggested
that, once outside the cell, augurin might be a plasma membrane-
associated protein in contact with and with the possibility of
secretion into CSF. To determine whether augurin is released into
CSF in vivo, we processed rat CSF for immunoblotting and
detected a 14 kDa band (Figure 1B) that corresponded to the
predicted molecular weight of augurin, the processed 118 amino
acid hormone-like peptide encoded by ECRG4(31–148) [18]. A
second higher MW band of unknown identity was also detected
which may reflect the peptide’s preponderance for aggregation
(unpublished observation).
To further address the subcellular distribution of augurin in CPe,
we biotinylated the cell surface of primary human CPe cells in
culture and fractionated the biotinylated proteins via preciptiation
with neutravidin beads. We then immunoblotted the cell-surface
fraction with an anti-augurin antibody [19]. Cultured CPe cells, like
many other cell types in culture that we have examined, do not
express endogenous Ecrg4 but could do so following gene delivery
with viral or plasmid vectors [14]. After infecting the CPe cells with
ADECRG4, a 14 kDa band was detected in whole cell lysates
(Figure 1C, left panel, lane 3). Likewise, a 14 kDa protein was
detected by immunoblotting of cell-surface proteins indicating that
augurin localizes to the cell surface (Figure 1C, middle panel, lane
3). Western blot analysis of the conditioned medium of CPe cells
however, in which we previously showed contained augurin (or an
immunoreactive fragment of augurin, which was quantified by
ELISA [14]), showed an immunoreactive peptide that was
approximately 6–8 kDa (Figure 1C, right panel, lane 3). This
suggests that, in our in vitro model, peptide cleavage releases (an)
augurin fragment(s) from the CPe cell surface. These data establish
that in vitro augurin is retained at the cell surface and that cell
surface proteolytic processing releases a smaller peptide into media
compared to what was detected in rat CSF. This raised the
possibility that two differently processed forms of augurin can be
shed by CPe cells and could be indicative of two peptide productes
each with a distince activity. No immunoreactivity was detected in
the whole cell lysates, cell surface fractions or conditioned media of
either untransduced or ADGFP transduced cells (Figure 1C, lanes 1
and 2).
Augurin distribution in choroid plexus changes after CNS
injury
We used a cortical lesion model of CNS injury [20] to evaluate
whether injury effected Ecrg4 gene expression and augurin
immunoreactivity in the lateral ventricle CPs. Control and injured
rats were killed at 1, 3, and 7 days after performing a 3 mm deep
lesion into the right cerebral cortex, lateral to the ventricles. As
shown in Figure 2, we observed by confocal microscopy that there
was significant diffuse staining in the normal, intact lateral
ventricle CP that appeared in many CPe cells to be polarized
towards the apical, ventricular facing surface of the epithelial cells
and with punctuated areas of immunofluorescent label (Figure 2A).
When evaluated 24 hours after injury (Figure 2B) the immuno-
staining signal was almost absent although there was some
immunoreactivity found in isolated foci. Even there however, the
overall intensity of staining appeared decreased. By 3 days after
the injury (Figure 2C), the immunostaining was still decreased
compared to control uninjured animals but it appeared more
uniformly distributed throughout the CP as compared to staining 1
day after the lesion. By 7 days, the intensity of staining was now
indistinguishable from control brains and there was a combined
pattern of polarized apical and focal punctate staining with a more
diffuse pattern of augurin immunoreactivity. Taken together, these
data suggest that augurin was mobilized immediately after CNS
injury and presumably released into CSF.
Ecrg4 is an injury response gene
The long term loss of immunoreactive augurin in CPe cells
following cortical lesion could be attributed to either (1) continuous
and expedited secretion-and-release of augurin depleting intracel-
lular stores or (2) lost augurin through decreased gene expression.
Accordingly, we used in situ hybridization to evaluate gene
expression in the choroid plexus after injury (Figure 3). An
antisense probe to rat Ecrg4 mRNA showed a strong signal in
uninjured control rat brains that resembled the pattern observed
for immunohistochemical staining (Figure 3A). The signal
appeared restricted to CPe cells and as with the protein, the
signal was lost 24 hours after injury (Figure 3B) and remained so
through to 3 days (Figure 3C) after which, it re-appeared by 7 days
(Figure 3D) to levels similar to those in control animals. The
signal detected in control animals and 7 days after injury was also
deemed specific because no hybridization was detected in CP
sections from sham or 7day post lesion animals that were treated
with a synthetic control probe (Figure 3E and F). Together, these
data suggest that Ecrg4 is an early injury response gene and that
the loss of augurin is biphasic: first due to bulk release from the cell
surface and intracellular storage vesicles and the second, due to the
loss of Ecrg4 gene expression throughout the proliferative phase of
injury.
Ecrg4 Response following Traumatic Brain Injury
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does not decrease after CNS injury
To examine whether augurin levels change in a pattern similar
to the CPe following cortical lesion, we looked for immunoreac-
tivity in another area of the brain with high levels of augurin
and Ecrg4 expression, the SON of the hypothalamus [21]. We
found no decrease in expression at 1 and 3 d.p.i. in injured rats
(Figure 4B and C) compared to control Figure 4A). This regional
comparison indicates the decreased levels of augurin at 1 and
3 d.p.i. are not a global response throughout the brain, and further
comparisons of anatomical regions will determine if this particular
pattern is unique to the CPe in response to CNS injury.
Discussion
The data presented here establish that CP-derived Ecrg4 is an
injury response gene. First, CNS injury precipitates a rapid loss of
Ecrg4 gene expression within 24 hours of injury and it remained
sustained for 7 days, at which time the injury has begun to resolve
Figure 1. Augurin (ECRG4(31–148)) localizes to the cell surface. Panel A: Immunohistochemical evidence for tethering at the cell surface: The
immunoreactive augurin recognized by this antibody in CP extracts was identified as the product of Ecrg4 by immunoblotting and demonstrating the
presence of a 14 kDa protein ECRG4(31–148) processed by cleavage of the 30 amino acid leader sequence as we determined previously [13]. Among
periventricular cells in the brain, polarized foci of punctated augurin staining were observed at the extracellular ventricular face of the choroid plexus
epithelial cell layer (red, arrow) in reference to nuclear counterstain (blue, DAPI). A granular staining pattern is observed in the cytoplasm if the CPe
cell layer, which is indicative of regulated vesicular secretion to the cell surface. Panel B: Detection of immunoreactive augurin in rat CSF:
Immunoblotting of rat CSF showed a 14 kDa band (arrow) that corresponds to the predicted molecular weight of augurin (ECRG4(31–148)). Panel C:
Biochemical evidence for cell surface tethering of augurin: Expression of Ecrg4 in the cultured CPe cells was detected neither by Western blot (left
panel) nor by RT-PCR of untransduced cells (not shown). Thus to study Ecrg4 in vitro it was necessary to use an adenovirus vector containing the
human Ecrg4 ORF. Protein was extracted from CPe cells 48 hours after no transduction or transduction with ADGFP or ADECRG4. The molecular weight
of Ecrg4-derived peptide fragments expressed in whole cell lysates was determined by Western blotting in the left panel. Cell-surface proteins were
fractionated by precipitation of Neutravidin-binding of biotinylated proteins on the cell surface (center panel) followed by Western blot analysis. The
peptide form secreted from cells was detected by direct Western blotting of conditioned medium (right panel).
doi:10.1371/journal.pone.0024609.g001
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bulk release of augurin from the CPe cell surface followed by more
sustained secretion and release of the intracellular stores of
augurin. The function of this bulk release in the earliest phase of
injury is not known but it was followed by a depletion of
immunoreactivity during the mid-phase of injury that was
exacerbated by a down regulation of Ecrg4 gene expression that
is sustained throughout the proliferative phase of CNS injury
through to resolution at day 7.
The Ecrg4 gene is a candidate tumor suppressor gene that has
gained significant attention because of the inverse association of
gene expression with the growth and progression of epithelial
cancers [23,24]. Down regulation is mediated by its epigenetic
silencing via DNA methylation of the Ecrg4 promoter [25,26,27].
Recently, Ecrg4 gene expression has also been inversely correlated
with cancer progression and invasiveness [27], anti-inflammatory
gene regulation through NF-kB [25], cell proliferation in the SVZ
[15] and directly correlated with increased senescence in the CNS
[15] and endocrine regulation of peripheral hydro-mineral
balance [21,28]. Its open reading frame (ORF) encodes a 148
amino acid protein that is highly conserved amongst species and
has secondary structure motifs that characterize neuropeptides
[13]. However, database mining reveals that Ecrg4 is not part
of a larger family of related genes. This could indicate tight
evolutionary control amongst Ecrg4 orthologs and a unique
biological function.
The decrease in augurin protein (Figure 2) and Ecrg4 gene
expression (Figure 3) occurs at times when cells proliferate in the
normal CNS injury response [29]. The time course of decreased
augurin correlates with the acute and sub-acute response times to
CNS injury [1] as both gene and protein expression are decreased
by 1 to 3 days post injury but return to uninjured levels by day 7.
This is consistent with our previous demonstration [14] that Ecrg4
gene expression is high in the normal CP and that Ecrg4
overexpression compromises neuroprogenitor cell growth and
differentiation. The findings presented here suggest that augurin
may be like a ‘‘sentinel’’ quiescence factor whose constitutive
presence is inhibitory, but whose absence becomes a dysinhibitory
signal that enables the proliferative response to injury.
The fact that Ecrg4 gene expression is epigenetically regulated
by DNA methylation raises the interesting possibility that the
constitutive levels of augurin in CP might be controlled epig-
enetically as well. If so, DNA methylation of Ecrg4 would control
the amounts of basal augurin that are constitutively present and
available for release during the acute stage of injury. The
significance of this hypothesis is not clear but it might signify
that DNA methylation could also gauge the return of gene expre-
ssion during the resolution phase of injury. Similar epigenetic
modifications in DNA methylation are now well described
after CNS ischemia and injury [30]. If reversal of such changes
influences recovery of augurin expression levels, then in view of the
effects of Ecrg4 gene knock down and over expression [30],
Figure 2. Augurin immunoreactivity decreases after CNS injury. A cortical stab wound decreased augurin protein levels in the contralateral
CP as determined by immunohistochemical staining and confocal microscopy. The ophthalmic knife penetrated the rat dorsal cortex to transect the
corpus callosum 3 mm deep and lateral to the right lateral ventricle. Immunoreactive augurin protein levels in the contralateral CP were decreased at
24 h (Panel B) and 3 days (Panel C) post injury compared to intact control animals (Panel A). By 7 days after injury augurin protein had returned to
approximately the same level as intact controls. Images representative of n=3 rats.
doi:10.1371/journal.pone.0024609.g002
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It is particularly noteworthy that, while augurin is similar to
other peptide hormones in that it is constitutively produced by the
CPe for secretion into CSF [22], it is also distinct from peptide
hormones in that cell surface tethering (Figure 1C) is reminiscent
of paracrine factors like epidermal and fibroblast growth factors,
notch, jagged and ephrins [31,32,33,34]. We [14] and others [15],
have previously described a release of augurin into conditioned
medium after transduction with Ecrg4 transgene, and we have
now shown detection of a 14 kDa form in rat CSF, the first
evidence of secreted augurin in vivo. Our findings of two different
forms of augurin produced by CPe, 6 kDa (in vitro) and 14 kDa
(in vivo), raise the possibility of different mechanisms of release.
The fact that two different immunoreactive forms were detected
could be a consequence of cell biology altered by the cell culturing
process, and it is possible that in response to injury the 6 kDa is
shed into CSF, while the 14 kDa form in Figure 1B is
constitutively released. The isoform detected could be dependent
on cell type and conditional: we have detected both isoforms in the
conditioned medium of transduced cultured prostate epithelial
cells (XD, manuscript in review) and the 6 kDa form in an ex vivo
model of inflammation (AK, manuscript in preparation). Figure 1C
supports the hypothesis that a tethered 14 kDa form is shed by
proteolysis into media. The form in CSF however (Figure 1B)
could be released by (1) removal of the membrane anchor, (2)
constitutive release from the ER/golgi pathway or (3) by another
cell type of origin.
The loss of augurin immunoreactivity in CPe tissue following
injury suggests that there are three pools of augurin: (1) peptide
released into biological fluids such as CSF, (2) protein retained at
the cell surface and (3) peptides stored in intracellular vesicles. The
immediate response to injury is presumably processing at the cell
surface and followed rapidly by augurin release from intracellular
storage vesicles. Gene expression levels following injury (Figure 3)
mirror protein levels (Figure 2) suggesting that the augurin
released shortly after injury is not replenished. The observation
that a smaller, processed form of augurin is found in conditioned
Figure 3. Ecrg4 gene expression decreases after CNS injury. Cortical stab wound decreased gene expression levels in the CP as determined
by in situ hybridization. The ophthalmic knife penetrated the rat dorsal cortex to transect the corpus callosum 3 mm deep and lateral to the right
lateral ventricle and Ecrg4 gene expression evaluated by binding of an Ecrg4 mRNA antisense probe in the contralateral CP in intact rat brains (Panel
A), 24 hrs (Panel B) 72 hrs (Panel C) and 7 days (Panel D) post-injury. A synthetic, negative control mRNA probe was generated from the pSPT18-Neo
plasmid control backbone and was used to assess background signal in Control (Panel E) and 7 day (Panel F) sections. Images representative of n=3
rats.
doi:10.1371/journal.pone.0024609.g003
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occur at the time of cell surface shedding. The biological function,
if any, of these fragments are not known but they may be distinct
from that of intact augurin tethered at the cell surface (Figure 5).
The results presented here are compatible with a dual function
model of augurin activity (Figure 5). Augurin normally acts as a
sentinel inhibitory factor that is constitutively present on the
epithelial cell surface but at early times after injury, augurin
fragments generated from the cell surface may be a permissive
signal for injury activation. The local decrease in augurin
concentration would dysinhibit proliferation and migration of
neuroprogenitor cells in the SVZ. Indeed, augurin overexpression
in CP and ependyma decreases BrdU uptake and nestin
immunoreactivity here, indicating that CPe-derived augurin
regulates the proliferation and lifespan of neuroprogenitors
[3,35,36]. Its dysinhibition could help divert progenitor migration
to the injury site from the rostral migratory stream [3,35,36]. If so,
the epigenetic regulation of Ecrg4 gene expression in the CP could
help guage the delicate balance between neuroprogenitor cell
mobilization in the SVZ for repair and repression of grown
inhibition. . Further kinetic analyses of augurin distribution and
Ecrg4 expression during the acute and chronic phases of recovery
from cortical lesions will address this possibility.
Materials and Methods
Animals
All studies using rats were conducted with prior approval of, and
in accordance with, either the Institutional Animal Care and Use
Committee at Brown University (Providence, RI, approval
numbers 0062-07 and 0073-10) or the Home Office at Birming-
ham University (Edgbaston, UK, approval number 3012720-
19b2). All survival surgeries were conducted under aseptic
conditions. Tissue was harvested from adult male Sprague Dawley
rats maintained in standard light/dark conditions with ad libitum
access to food and water. For brain tissue harvesting, rats were
killed by CO2 inhalation and immediately perfused with 4%
paraformaldehyde (PFA) in phosphate-buffered saline (PBS).
Brains were removed and further fixed overnight in PBS
containing 20% sucrose and 4% PFA at 4uC. The, brains were
incubated in PBS containing 30% sucrose overnight and frozen in
OCT compound on dry ice and stored at 280uC until further
processing.
Antibodies
Immunofluorescence. A polyclonal IgY antibody was raised
in chickens against recombinant human ECRG4(71–148) and
antigen affinity purified by commercial contract with GenWay
Biotech, Inc., (San Diego, CA). Purified pre-immune IgY from the
same animal was used as a negative control in immunostaining of
rat brain tissue and goat anti-chicken-AlexaFluorH 594 (Life
Technologies, Carlsbad, CA) was used for detection. Western
blotting: Affinity purified rabbit anti- human ECRG4 primary
antibody (Sigma-Aldrich, St. Louis, MO) and Goat anti-rabbit–
Horseradish Peroxidase (HRP) conjugated secondary antibody
(JacksonImmuno Labs, West Grove, PA) were used to detect
protein in Western blotting analysis.
Figure 4. Augurin immunoreactivity in the supraoptic nucleus (SON) of the hypothalamus does not decrease following penetrating
CNS injury. To demonstrate specificity of injury response in the CPe as opposed to other regions of the brain that have high levels of Ecrg4 gene
and augurin protein expression [21], we examined the SON of the hypothalamus in injured rats at 1 (Panel B), 3 (Panel C) and 7 (Panel D) d.p.i. and
compared staining in intact brain (Panel A). While there may have been a slight incrase at 3 and 7 d.p.i., the precipitous decline of expression that
occurred in the CPe following injury was not observed in SON. Images representative of n=3 rats.
doi:10.1371/journal.pone.0024609.g004
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An adenovirus vector containing a transgene for the human
Ecrg4 ORF (ADECRG4) was prepared as described previously.
An adenovirus containing the transgene for green fluorescent
protein (ADGFP, Vector BioLabs, Philadelphia, PA) was used as a
control.
Cell Culture
A primary human CP epithelial cell line was purchased from
ScienCell Research Laboratories (Carlsbad, CA) and cultured in
Epithelial Cell Medium according to manufacturer’s instructions.
For adenovirus infection, confluent cells were counted and
transduced with a multiplicity of infection (MOI) of 20.
Penetrating CNS Lesion Model
Rats were anesthetized with 5% isoflurane in oxygen (1.7 L/
min) and given 0.3 mg/kg buprenorphine subcutaneously for
analgesia prior to CNS injury. Anesthesia was assessed by paw
pinch reflex. The skull was first exposed with a sagital incision
along the midline of the head and after creating a burr hole
through the dura with a dental drill, a lesion was made 3 mm right
of bregma, 7.5 mm rostral of the ear-bar plane and 3 mm deep
using an ophthalmic knife (Unitome Knife, BD Waltham, MA).
The injury inflicted transected the corpus callosum and the knife
wound entered the striatum. We have used this injury model
extensively in other studies [37,38,39,40]. Intact rat brains from
un-operated animals were used as controls.
Collection of rat CSF
CSF samples from adult Spragu-Dawley rats were collected as
described previously [41]. Briefly, rats were deeply anaesthetized
in a stereotaxic frame with the head raised above the body. An
incision was made from the top of the head to the base of the neck.
The muscle was retracted from around the base of the skull. Using
a Hamilton syringe, CSF was withdrawn from the cisterna magna
and immediately frozen on dry ice. Rats were then killed by
terminal anesthesia.
Cell Surface Protein Fractionation and Immunoblotting
Primary human CPe cells were infected with ADECRG4 or
ADGFP a MOI of 20 to overexpress either Ecrg4 or GFP. Cell
surface proteins were biotinylated and pulled down using the Cell
Surface Protein Isolation Kit according to manufacturer’s
instructions (Pierce, Rockford, IL). Precipitated proteins were
eluted from Neutravidin beads by incubating in 2% lithium
dodecyl sulfate sample buffer under reducing conditions for one
hour at 25uC. Immunoreactive protein was detected by Western
blotting. Briefly, proteins were size fractionated on a 4–12% Bis-
Tris gel for SDS-PAGE. Proteins were transferred to 0.2 mm
polyvinylidene fluoride membrane, which was blocked with 5%
bovine serum albumin (BSA) solution for one hour at 25uC.
Rabbit anti-human augurin (Sigma-Aldrich, St. Louis, MO) was
diluted in 1% BSA at a concentration of 0.5 mg/ml and incubated
with the membrane overnight at 4uC. Following washes with PBS
containing 0.05% Tween-20, the membranes were incubated with
Figure 5. A biphasic model for augurin activity and CNS dysinhibition. Normal choroid plexus epithelia express Ecrg4 and contain
significant 14 kDa augurin protein that is in an inhibitory conformation. The unprocessed peptide is contained in 3 compartments (1) intracellular
vesicles (i.e. punctate intracellular staining in Figure 1) (2) near the ventricular cell surface (i.e. polarized apical staining of cells in Figure 1 and (3)
tethered at the cell surface (i.e. Figure 1B). Upon injury, the sudden release and processing at the cell surface is followed by release from intracellular
stores as a ‘‘panic signal’’ to indicate systemic injury. The initial pro-inflammatory response then shuts down Ecrg4 gene expression for at least 1 to3
days post-injury. Therefore, during the initial phase of injury, its normal, constitutively inhibitory functions are absent and so repair cells proliferate. As
gene expression returns, quiescence is restored and homeostasis re-established.
doi:10.1371/journal.pone.0024609.g005
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1% BSA for one hour at 25uC, rinsed and then incubated with
Super Signal West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL). Bioluminescence signal was detected by imaging
with an IVISH Lumina imaging system (Caliper Life Sciences,
Hopkinton, MA).
Immunostaining of Rat Brain Tissue
Frozen rat brains with and without lesions were cut into 15 mmm
sections for immunohistochemistry. Briefly, non-specific protein
binding was blocked in PBS containing 0.3% Tween-20, 2% BSA
and 15% normal goat serum. Samples were rinsed and incubated
overnight at 4uC with 0.5 mg/ml chicken anti-augurin antibody.
After washing, sections were incubated with either 1 mg/ml goat
anti-chicken Alexa FluorH 594 (Figure 1) or Alexa FluorH 488
(Figure 2) secondary antibody for 45 min at room temperature.
Sections were rinsed and mounted with Vectashield containing
DAPI (Vector Labs, Burlingame, CA).
In Situ Hybridization
Sections from control and injured rats were processed and
sectioned as for immunohistochemistry. Digoxigenin labeled
antisense RNA probe to rat Ecrg4 cDNA was synthesized with
the DIG RNA Labeling Kit (Roche, Indianapolis, IN) and
hybridized to tissue as described previously [14].
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